The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
Clinical Surgical Oncology · 2024-12 · 3 (4) · 100069
DOI: 10.1016/j.cson.2024.100069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Surgical Oncology, 2024-12. Verfasst von Shangshang Ma und 7 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science and Technology Project of Zhejiang Province, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Adjuvant chemotherapy (ACT) remains the current first-line systemic treatment option for patients with KRAS -mutated lung adenocarcinoma (LUAD), but the response is not effective. The prognosis of ACT in patients with KRAS mutations in stage I LUAD has not yet been effectively explored. Detailed data about patients with stage I LUAD from Shanghai Pulmonary Hospital were collected in this ambispective study. Pearson's Chi-square test, Kaplan-Meier analysis, and Cox proportional hazard models were performed in this study. The primary observational endpoint was overall survival (OS). Sensitivity analysis was performed to assess the robustness of the findings. In this study population, 10.87% (194 out of 1783) of stage I LUAD patients possessed KRAS mutations. In the KRAS -mutated cohort, 7 patients harbored EGFR L858R point mutation, 2 patients exhibited EGFR exon 19 Del mutation, 2 patients had ALK rearrangement, and 1 patient for other EGFR mutations. Patients harboring KRAS mutations had a worse OS compared to KRAS wild-type (WT) patients (5-year OS rate: 96% vs. 82%, P < 0.001). In addition, the KARS(G12C) mutation was an independent factor for poor prognosis ( P < 0.001). Importantly, ACT improved survival in patients with stage IB LUAD ( P = 0.02) while not improved survival in the group of stage IB patients with KRAS mutations ( P = 0.31). KRAS mutation could co-occur with EGFR mutation and ALK rearrangement. KRAS mutation was associated with poor prognosis in stage I LUAD patients. In addition, ACT did not improve prognosis in stage IB LUAD patients with KRAS mutations. Our findings require more research to be confirmed. • KRAS mutation is a prognosticator for stage I LUAD associated with poor survival. • The proportion of KRAS mutation was around 10.9%. • KRAS mutation could co-occur with EGFR mutations or ALK rearrangements. • Adjuvant chemotherapy was not effective in KRAS mutation patients.
Förderung
- Medical Science and Technology Project of Zhejiang Province
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Ma, S., Li, K., Wang, R., Qian, J., Fan, Y., Qin, X., Li, M., & Wu, L. (2024). The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma. Clinical Surgical Oncology, 3(4), 100069. https://doi.org/10.1016/j.cson.2024.100069
Vancouver
Ma S, Li K, Wang R, Qian J, Fan Y, Qin X, et al. The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma. Clinical Surgical Oncology. 2024;3(4):100069. doi:10.1016/j.cson.2024.100069
BibTeX
@article{Ma2024,
author = {Ma, Shangshang and Li, Kun and Wang, Rangrang and Qian, Jiayi and Fan, Yongfei and Qin, Xichun and Li, Mingjun and Wu, Leilei},
title = {The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma},
journal = {Clinical Surgical Oncology},
year = {2024},
volume = {3},
number = {4},
pages = {100069},
doi = {10.1016/j.cson.2024.100069}
}
EUVIMED